Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

Transplantation

Volumn 66, Issue 8, 1998, Pages 1040-1046

  Kahan, Barry D ^a   Podbielski, Jeanette ^a   Napoli, Kimberly L ^a   Katz, Stephen M ^a   Meier Kriesche, Herwig Ulf ^a   Van Buren, Charles T ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; PREDNISOLONE; PREDNISONE; RAPAMYCIN;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISONE; SIROLIMUS;

EID: 0032573044     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199810270-00013     Document Type: Article

References (33)

1. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
2. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 877.
3. Stepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 1991; 51: 22.
4. Kahan BD, Chang JY, Seghal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185.
5. Knight R, Ferraresso M, Serino F, Katz SM, Lewis R, Kahan BD. Low dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55: 947.
6. Ochiai T, Gunji Y, Nagata M, Komori A, Asano T, Isono K. Effects of rapamycin in experimental organ allografting. Transplantation 1993; 56: 15.
7. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 59: 183.
8. Martel RR, Klicius Y, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48.
9. Carlson RP, Baeder WL, Caccese RG, Warner LM, Sehgal SN. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann NY Acad Sci 1993; 23: 86.
10. Warner LM, Adams LN, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37: 289.
11. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 S6 kinase activity of FRAP in vivo. Nature 1995; 377: 441.
12. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570.
13. cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268: 22737.
14. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
15. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209.
16. Zimmerman J, Kahan BD. The pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405.
17. Kahan BD, Welsh M, Rutzky L, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992; 53: 345.
18. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
19. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599.
20. Kahan BD, Kerman RH, Van Buren CT, Flechner SM, Golden DL, Lewis RM. Clinical outcome in 36 patients after at least one and up to five years of steroid withdrawal based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor. Transplant Proc 1989; 21: 1579.
21. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
22. Lindholm A, Napoli K, Rutzky L, Kahan BD. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area under the curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 1992; 14: 292.
23. Napoli KL, Kahan BD. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem 1996; 42: 1944.
24. Kahan BD, Flechner SM, Lorber MI, Jensen C, Golden DL, Van Buren CT. Complications of cydosporin therapy. World J Surg 1986; 10: 348.
25. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
26. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37.
27. Mulloy LL, Wright F, Hall ML, M Moore, The US Simulect Study Group. Basiliximab (Simulect) reduces acute cellular rejection in renal allografts from cadaveric and living donors. 17th Annual Meeting of the American Society of Transplant Physicians, 1998; 749.
28. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51: 465.
29. Rideout DC, Chou TC. Introduction. In: Chou TC, Rideout DC, eds. Synergism, antagonism, and potentiation in chemotherapy. San Diego: Academic Press, 1991: 3.
30. Groth CG, The European Sirolimus Renal Transplant Study Group. Early efficacy results from a pilot study of sirolimus versus cyclosporine in association with azathioprine and corticosteroids in the prevention of acute rejection in human renal allograft recipients. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons, 1997; A-223.
31. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53.
32. Kahan BD, Gibbons S, Tejpal N, Stepkowski S, Chou TC. Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances for normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
33. Quesniaux VFJ, Wehrli S, Steiner C, et al. The immunosuppressive rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 1994; 84: 1543.